Huang, Y., Zhou, J., Zhan, Z., Ke, L., Xia, W., Cao, X., . . . Lv, X. (2023). Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: Development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose. BMC.
Chicago Style (17th ed.) CitationHuang, Ying-Ying, et al. Tumor Residue in Patients with Stage II–IVA Nasopharyngeal Carcinoma Who Received Intensity-modulated Radiation Therapy: Development and Validation of a Prediction Nomogram Integrating Postradiotherapy Plasma Epstein–Barr Virus Deoxyribonucleic Acid, Clinical Stage, and Radiotherapy Dose. BMC, 2023.
MLA (9th ed.) CitationHuang, Ying-Ying, et al. Tumor Residue in Patients with Stage II–IVA Nasopharyngeal Carcinoma Who Received Intensity-modulated Radiation Therapy: Development and Validation of a Prediction Nomogram Integrating Postradiotherapy Plasma Epstein–Barr Virus Deoxyribonucleic Acid, Clinical Stage, and Radiotherapy Dose. BMC, 2023.